[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Näppi J, Yoshida H: Adaptive correction of the pseudo-enhancement of CT attenuation for fecal-tagging CT colonography. Med Image Anal; 2008 Aug;12(4):413-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fecal-tagging CT colonography (ftCTC), positive-contrast tagging agents are used for opacifying residual bowel materials to facilitate reliable detection of colorectal lesions.
  • However, tagging agents that have high radiodensity tend to artificially elevate the observed CT attenuation of nearby materials toward that of tagged materials on Hounsfield unit (HU) scale.
  • The ADC method was optimized by use of an anthropomorphic phantom filled partially with three concentrations of a tagging agent.
  • The effect of ADC on ftCTC was assessed visually and quantitatively by comparison of the accuracy of computer-aided detection (CAD) without and with the use of the ADC method in two different types of clinical ftCTC databases: 20 laxative ftCTC cases with 24 polyps, and 23 reduced-preparation ftCTC cases with 28 polyps.
  • With ADC, the free-response receiver operating characteristic curves indicating CAD performance in polyp detection yielded normalized partial area-under-curve values of 0.91 and 0.80 for the two databases, respectively, with statistically significant improvement over conventional thresholding-based approaches (p<0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Nov;213(2):468-72 [10551228.001]
  • [Cites] N Engl J Med. 2007 Oct 4;357(14):1403-12 [17914041.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1261-74 [11811826.001]
  • [Cites] Acad Radiol. 2002 Apr;9(4):386-97 [11942653.001]
  • [Cites] Radiology. 2002 Aug;224(2):393-403 [12147834.001]
  • [Cites] Radiology. 2003 Mar;226(3):911-7 [12601218.001]
  • [Cites] Radiology. 2003 May;227(2):378-84 [12732696.001]
  • [Cites] Med Phys. 2003 Jul;30(7):1592-601 [12906177.001]
  • [Cites] Phys Med Biol. 2003 Aug 7;48(15):2453-77 [12953909.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Phys Med Biol. 1976 May;21(3):390-8 [778862.001]
  • [Cites] Radiology. 1981 Oct;141(1):223-7 [7291529.001]
  • [Cites] Med Phys. 1982 Jul-Aug;9(4):464-72 [7110075.001]
  • [Cites] AJR Am J Roentgenol. 1982 Sep;139(3):443-7 [6981306.001]
  • [Cites] Clin Chem. 1993 Sep;39(9):1998-2004 [8375090.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):186-92 [9107614.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1300-11 [15520999.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):105-8 [15615958.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1836-42 [15908539.001]
  • [Cites] Radiology. 2005 Jul;236(1):118-24 [15987967.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):389-94 [16492934.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Acad Radiol. 2007 Mar;14(3):287-300 [17307661.001]
  • [Cites] Med Phys. 2007 Mar;34(3):871-6 [17441232.001]
  • [Cites] Comput Med Imaging Graph. 2007 Jun-Jul;31(4-5):267-84 [17376650.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):666-71 [17550745.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Sep;20(9):886-99 [11585206.001]
  • (PMID = 18313349.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095279-06; United States / NCI NIH HHS / CA / R01 CA095279-06; United States / NCI NIH HHS / CA / R01 CA095279-05; United States / NCI NIH HHS / CA / CA095279-04; United States / NCI NIH HHS / CA / R56 CA095279; United States / NCI NIH HHS / CA / CA095279-05; United States / NCI NIH HHS / CA / R01 CA095279-04; United States / NCI NIH HHS / CA / R01 CA131718; United States / NCI NIH HHS / CA / CA095279; United States / NCI NIH HHS / CA / R01 CA095279
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS62173; NLM/ PMC2762861
  •  go-up   go-down


2. Hadar T, Shvero J, Yaniv E, Shvili I, Leabu M, Koren R: Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp. J Cell Mol Med; 2008 Sep-Oct;12(5A):1551-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp.
  • Our goal was to investigate by immunochemistry the expression level of topoII-in inverted papilloma, inflammatory nasal polyp and normal sinonasal epithelium and to compare it with expression level of Ki67.
  • In inflammatory nasal polyp group, topoII-alpha index was 2.4 +/- 2.1, and the difference in the topoII-alpha index between inverted papilloma and inflammatory polyp group was also statistically significant.
  • In the inflammatory nasal polyp group Ki67 index was 5.9 +/- 3.4.
  • The difference in th Ki67 index between inverted papilloma and inflammatory nasal polyp groups was statistically significant.
  • These results suggest that the inverte papilloma contains a significantly higher cell population with proliferative activity by comparison with normal sinonasal and inflammatory polyp epithelia, showing a significant correlation between topoII-alpha and Ki67 expression, and indicating that topoII-alpha could be a independent prognostic factor for a putative malignant transformation.
  • [MeSH-major] Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Nose Neoplasms / enzymology. Nose Neoplasms / pathology. Papilloma, Inverted / enzymology. Papilloma, Inverted / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelium / enzymology. Female. Humans. Inflammation / enzymology. Inflammation / pathology. Ki-67 Antigen / metabolism. Male. Middle Aged. Nasal Polyps / enzymology. Nasal Polyps / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544048.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC3918071
  •  go-up   go-down


3. Jagannathan V, Kaur P, Datta S: Polyphosphate kinase from M. tuberculosis: an interconnect between the genetic and biochemical role. PLoS One; 2010;5(12):e14336
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The enzyme Polyphosphate Kinase (PPK) catalyses the reversible transfer of the terminal γ-Pi of ATP to form a long chain Polyphosphate (PolyP).
  • PPK thus seems to be a suitable anti-tubercular drug target.
  • The enzyme displayed a strong product inhibition by ADP.
  • In order to accurately estimate the product inhibition, progress curve analysis of the enzyme reaction was monitored.
  • The kinetic equation describing the progress curve was suitably modified by taking into account the product inhibition.
  • [MeSH-minor] Adenosine Diphosphate / chemistry. Adenosine Triphosphate / chemistry. Antitubercular Agents / pharmacology. Cloning, Molecular. Down-Regulation. Escherichia coli / metabolism. Gene Expression Regulation, Bacterial. Gene Expression Regulation, Enzymologic. Kinetics. Models, Genetic. Models, Statistical. Tolonium Chloride / pharmacology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Sep 15;308(2):294-9 [12419342.001]
  • [Cites] Microbiology. 2010 Jan;156(Pt 1):81-7 [19797356.001]
  • [Cites] J Biol Chem. 1965 Nov;240(11):4427-34 [5845843.001]
  • [Cites] J Biol Chem. 2000 Feb 11;275(6):3977-83 [10660553.001]
  • [Cites] Biochemistry (Mosc). 2000 Mar;65(3):271-8 [10739469.001]
  • [Cites] Biochemistry (Mosc). 2000 Mar;65(3):309-14 [10739473.001]
  • [Cites] Annu Rev Biochem. 1999;68:89-125 [10872445.001]
  • [Cites] Anal Biochem. 2000 Dec 15;287(2):329-33 [11112281.001]
  • [Cites] Annu Rev Microbiol. 2001;55:139-63 [11544352.001]
  • [Cites] J Biol Chem. 1986 Apr 5;261(10):4481-5 [3007459.001]
  • [Cites] Infect Immun. 1993 Sep;61(9):3703-10 [8395468.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6290-5 [8119977.001]
  • [Cites] Nucleic Acids Res. 1994 Sep 11;22(18):3801-5 [7937094.001]
  • [Cites] J Bacteriol. 1996 Mar;178(5):1394-400 [8631717.001]
  • [Cites] Infect Immun. 1996 Jun;64(6):2062-9 [8675308.001]
  • [Cites] J Bacteriol. 1998 Apr;180(7):1841-7 [9537383.001]
  • [Cites] J Bacteriol. 1999 Jan;181(2):469-76 [9882660.001]
  • [Cites] Mol Microbiol. 2007 Jul;65(2):261-76 [17630969.001]
  • [Cites] Cell. 2007 Sep 7;130(5):797-810 [17803904.001]
  • [Cites] J Biol Chem. 2008 Sep 12;283(37):25273-80 [18625705.001]
  • [Cites] Annu Rev Biochem. 2009;78:605-47 [19344251.001]
  • [Cites] PLoS One. 2009;4(6):e5923 [19526063.001]
  • [Cites] Mol Microbiol. 2009 Dec;74(5):1187-97 [19843229.001]
  • [Cites] Tuberculosis (Edinb). 2004;84(1-2):29-44 [14670344.001]
  • (PMID = 21179463.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 15XUH0X66N / Tolonium Chloride; 61D2G4IYVH / Adenosine Diphosphate; 8L70Q75FXE / Adenosine Triphosphate; EC 2.7.4.- / Phosphotransferases (Phosphate Group Acceptor); EC 2.7.4.1 / polyphosphate kinase
  • [Other-IDs] NLM/ PMC3002279
  •  go-up   go-down


Advertisement
4. Linguraru MG, Zhao S, Van Uitert RL, Liu J, Fletcher JG, Manduca A, Summers RM: CAD of colon cancer on CT colonography cases without cathartic bowel preparation. Conf Proc IEEE Eng Med Biol Soc; 2008;2008:2996-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAD of colon cancer on CT colonography cases without cathartic bowel preparation.
  • Computer-aided diagnosis (CAD) systems must show sufficient versatility to produce robust analysis on a large variety of data.
  • In the case of colonography, CAD has not been designed to cope with the presence of stool, although labeling the stool with high contrast agents replaces the use of laxatives and reduces the patient discomfort.
  • This procedure introduces additional challenges for the diagnosis, such as poorly tagged stool, stool sticking to colonic walls, and heterogeneous stool (tagged stool mixed with air or untagged stool).
  • Colonoscopy data are automatically cleansed of residual stool to enhance the polyp appearance for improved diagnosis.
  • Results show stool removal accuracy on polyps which are partially or fully covered by stool.
  • The automatic detection of colon polyps using our CAD system on cathartic-free data improves considerably with the addition of the automatic stool removal module from 74% to 86% true positive (TP) rate at 6.4 false positives (FP)/case.
  • [MeSH-major] Colon / diagnostic imaging. Colon / pathology. Colonography, Computed Tomographic / methods. Diagnosis, Computer-Assisted / methods. Pattern Recognition, Automated / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Sep;5(3):195-206 [11524226.001]
  • [Cites] Radiology. 2003 May;227(2):378-84 [12732696.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1832-44 [16344052.001]
  • [Cites] IEEE Trans Biomed Eng. 2006 Aug;53(8):1635-46 [16916098.001]
  • [Cites] AJR Am J Roentgenol. 2008 Feb;190(2):361-6 [18212221.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):32-42 [17404739.001]
  • (PMID = 19163336.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CL999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Laxatives
  • [Other-IDs] NLM/ NIHMS69939; NLM/ PMC2630581
  •  go-up   go-down


5. Zakharash MP, Poĭda OI: [Application of preparations relief ultra and relief advance in practice of coloproctological department]. Klin Khir; 2005 Oct;(10):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of preparations relief ultra and relief advance in practice of coloproctological department].
  • Efficacy of application of preparations Relief Ultra and Relief Advance as pathogenetically directed medicines was established, basing on analysis of the examination and treatment results in 133 patients with anal region diseases (acute and chronic hemorrhoids, nonspeciphic ulcerative colitis, the Crohn's disease, acute paraproctitis, rectal polyp).
  • For local conservative treatment it is expedient to apply preparations in various pharmacological forms in complex.
  • Application of preparation Relief Ultra endorectally in conjunction with preparation Relief Advance endorectally and locally on the wound surface is indicated after performance of elective and urgent operative interventions for rectal and anal zone diseases.

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ZINC SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509076.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fish Oils; 0 / Suppositories; 3X7931PO74 / hydrocortisone acetate; 7733-02-0 / Zinc Sulfate; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


6. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW: Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology; 2004 Feb;126(2):425-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemoprevention with the nonsteroidal anti-inflammatory drug sulindac was evaluated.
  • Among the subset of patients taking sulindac, 3 of 5 prostaglandin levels were statistically significantly lower in patients who were polyp free than in those who developed polyps.
  • By contrast, there were no statistically significant differences in ornithine decarboxylase or polyamines between treatment groups or in those on sulindac who were polyp free compared with those who developed polyps.
  • CONCLUSIONS: Colorectal mucosal prostaglandin levels, but not ornithine decarboxylase or polyamines, may be valuable biomarkers to assess appropriate drug dosage and medication compliance in patients undergoing primary chemoprevention therapy with sulindac.
  • Reduction of mucosal prostaglandin levels may be necessary to achieve chemopreventive benefit from this agent.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Nov;44(11):4924-8 [6488154.001]
  • [Cites] Cell. 1991 Aug 9;66(3):601-13 [1678319.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4449-52 [3731101.001]
  • [Cites] J Chromatogr. 1986 Jul 11;380(1):19-32 [3745383.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1275-81 [3621111.001]
  • [Cites] Ann Surg. 1988 Jun;207(6):662-9 [3389934.001]
  • [Cites] J Surg Oncol. 1988 Aug;38(4):240-3 [3411968.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):639-43 [2535963.001]
  • [Cites] J Natl Cancer Inst. 1989 Mar 15;81(6):421-7 [2493096.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1061-6 [2758383.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4528-34 [1831401.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):369-74 [8348060.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Gut. 1994 May;35(5):675-8 [8200564.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):813-30 [7634976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):37-48 [8993796.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):199-201 [9000553.001]
  • [Cites] Dig Dis Sci. 1998 Feb;43(2):311-6 [9512123.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1750-3 [9563494.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2000 Jan;60(1-3):83-96 [10680778.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Scand J Gastroenterol. 2001 Aug;36(8):865-9 [11495083.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2069-72 [2009526.001]
  • [Cites] Dis Colon Rectum. 1991 Jul;34(7):572-6 [2055143.001]
  • [Cites] Histochem Cell Biol. 2001 Aug;116(2):171-81 [11685545.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Am J Physiol. 1982 Nov;243(5):C212-21 [6814260.001]
  • [Cites] J Surg Oncol. 1983 Sep;24(1):83-7 [6887943.001]
  • [Cites] Methods Enzymol. 1983;94:158-61 [6621384.001]
  • [Cites] N Engl J Med. 1984 Jul 12;311(2):80-3 [6738598.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3226-30 [6430547.001]
  • [Cites] Br J Surg. 1984 Oct;71(10):791-4 [6487981.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):117-20 [2062082.001]
  • [Cites] Gastroenterology. 1991 Sep;101(3):635-9 [1650315.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):89-93 [3729588.001]
  • (PMID = 14762779.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R24 DK064399-01; United States / NIDDK NIH HHS / DK / DK064399-01; United States / NCI NIH HHS / CA / CA 51085; United States / NCI NIH HHS / CA / CA 53801; United States / NIDDK NIH HHS / DK / R24 DK064399; United States / NCI NIH HHS / CA / CA 63721; United States / NCI NIH HHS / CA / P50 CA 93-16
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Polyamines; 0 / Prostaglandins; 184SNS8VUH / Sulindac; EC 4.1.1.17 / Ornithine Decarboxylase
  • [Other-IDs] NLM/ NIHMS38268; NLM/ PMC2225536
  •  go-up   go-down


7. Kuhne HP, Göller T, Schneider I, Bozkurt T, Becker HP: [Unclear per anum bleeding during pregnancy]. Chirurg; 2005 Aug;76(8):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rectoscopy showed the cause to be a polyp the size of a fingertip 9 cm from the anus.
  • About 1 year later, the same patient experienced sharp pains and anal bleeding during defecation.
  • [MeSH-major] Intestinal Polyps / diagnosis. Melena / etiology. Neuroendocrine Tumors / diagnosis. Pregnancy Complications / etiology. Pregnancy Complications, Neoplastic / diagnosis. Puerperal Disorders / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Disease Progression. Female. Humans. Infant, Newborn. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Rectum / pathology. Rectum / surgery


8. Luebeck EG, Moolgavkar SH: Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A; 2002 Nov 12;99(23):15095-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We use general multistage models to fit the age-specific incidence of colorectal cancers in the Surveillance, Epidemiology, and End Results registry, which covers approximately 10% of the U.S. population, while simultaneously adjusting for birth cohort and calendar year effects.
  • The incidence of colorectal cancers in the Surveillance, Epidemiology, and End Results registry is most consistent with a model positing two rare events followed by a high-frequency event in the conversion of a normal stem cell into an initiated cell that expands clonally to give rise to an adenomatous polyp.
  • The model also predicts that interventions, such as administration of nonsteroidal anti-inflammatory drugs, designed to decrease the growth rate of adenomatous polyps, are very efficient at lowering colon cancer risk substantially, even when begun later in life.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Sep 1;83(5):896-900 [9731892.001]
  • [Cites] Mutat Res. 1998 May 25;400(1-2):553-78 [9685710.001]
  • [Cites] Nat Med. 1999 Jan;5(1):11-2 [9883827.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Trends Cell Biol. 1999 Dec;9(12):M57-60 [10611684.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):379-85 [10688858.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3352-7 [10737795.001]
  • [Cites] Cell Prolif. 2000 Feb;33(1):1-18 [10741640.001]
  • [Cites] Annu Rev Med. 2000;51:511-23 [10774479.001]
  • [Cites] J Theor Biol. 2000 Nov 21;207(2):129-43 [11034825.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2640-5 [11226292.001]
  • [Cites] Gut. 2001 May;48(5):660-6 [11302965.001]
  • [Cites] Math Biosci. 2001 Jun;171(2):113-42 [11395047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10839-44 [11517339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3076-80 [11867767.001]
  • [Cites] Int J Cancer. 1969 Jan 15;4(1):93-112 [5346480.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Int Rev Cytol. 1984;90:309-73 [6389415.001]
  • [Cites] Risk Anal. 1988 Sep;8(3):383-92 [3201016.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):287-94 [1706308.001]
  • [Cites] Development. 1990 Dec;110(4):1001-20 [2100251.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 15;84(8):610-8 [1313509.001]
  • [Cites] Science. 1993 May 7;260(5109):810-2 [8484120.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Nat Med. 1995 Sep;1(9):902-9 [7585215.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681-6 [9435252.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • (PMID = 12415112.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047658; United States / NCI NIH HHS / CA / P01 CA76466; United States / NCI NIH HHS / CA / R01 CA47658
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC137549
  •  go-up   go-down


9. Liu J, Yao J, Summers RM: Scale-based scatter correction for computer-aided polyp detection in CT colonography. Med Phys; 2008 Dec;35(12):5664-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scale-based scatter correction for computer-aided polyp detection in CT colonography.
  • CT colonography (CTC) is a feasible and minimally invasive method for the detection of colorectal polyps and cancer screening.
  • Computer-aided detection (CAD) of polyps can improve consistency and sensitivity of virtual colonoscopy interpretation and reduce interpretation burden.
  • However, high-density orally administered contrast agents have scatter effects on neighboring tissues.
  • This pseudoenhancement phenomenon presents a problem for the application of computer-aided polyp detection, especially when polyps are submerged in the contrast agents.
  • By bringing a locally adaptive structure, object scale, into the correction framework, the region of neighboring tissues affected by contrast agents is automatically specified and adaptively changed in different parts of the image.
  • There were 50 colonoscopy-confirmed polyps measuring 6-9 mm.
  • Visual evaluation indicated that the method reduced CT attenuation of pseudoenhanced polyps to the usual polyp Hounsfield unit range without affecting luminal air regions.
  • For polyps submerged in contrast agents, the sensitivity of CAD with correction is increased 24% at a rate of ten false-positive detections per scan.
  • For all polyps within 6-9 mm, the sensitivity of the authors' CAD with scatter correction is increased 8% at a rate of ten false-positive detections per scan.
  • [MeSH-major] Colon / diagnostic imaging. Colonography, Computed Tomographic / methods. Diagnosis, Computer-Assisted / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Algorithms. Automation. Colonoscopy / methods. Contrast Media / pharmacology. False Positive Reactions. Humans. Pattern Recognition, Automated. Polyps. Radiographic Image Interpretation, Computer-Assisted / methods. Reproducibility of Results. Scattering, Radiation

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):51-9 [11274534.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Aug;20(8):689-703 [11513021.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Nov;20(11):1140-55 [11700740.001]
  • [Cites] Radiology. 2002 Nov;225(2):391-9 [12409571.001]
  • [Cites] Med Phys. 1982 Jul-Aug;9(4):464-72 [7110075.001]
  • [Cites] Med Image Anal. 2008 Aug;12(4):413-26 [18313349.001]
  • [Cites] Radiology. 2005 Jul;236(1):118-24 [15987967.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1193-8 [15924230.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1832-44 [16344052.001]
  • [Cites] Med Phys. 2006 Jan;33(1):187-97 [16485425.001]
  • [Cites] Med Phys. 2007 May;34(5):1655-64 [17555247.001]
  • [Cites] Med Phys. 1987 May-Jun;14(3):335-40 [3600521.001]
  • (PMID = 19175123.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CL040003-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS84353; NLM/ PMC2644449
  •  go-up   go-down


10. Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, Smalley WE, Shyr Y, Sinha R, Ness RM, Hein DW, Zheng W: Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev; 2008 Feb;17(2):320-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk.
  • Most colorectal cancers arise from adenomatous polyps or certain hyperplastic polyps.
  • Only a few studies have investigated potential genetic modifiers of the associations between meat intake and polyp risk, and results are inconsistent.
  • Using data from the Tennessee Colorectal Polyp Study, a large colonoscopy-based study, including 1,002 polyp cases (557 adenoma only, 250 hyperplastic polyp only, 195 both polyps) and 1,493 polyp-free patients, we evaluated the association of colorectal polyp risk with carcinogen exposure from meat and genetic polymorphisms in enzymes involved in heterocyclic amine (HCA) metabolism, including N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2), cytochrome P450 1A2 (CYP1A2), and aryl hydrocarbon receptor (AhR).
  • Data on intake levels of meats by preparation methods, doneness preferences, and other lifestyle factors were obtained.
  • No clear association was found for any polymorphisms with polyp risk.
  • However, apparent interactions were found for intake of meat and HCAs with AhR, NAT1, and NAT2 genotypes, and the interactions were statistically significant for the group with both adenomatous and hyperplastic polyps.
  • These results provide strong evidence for a modifying effect of metabolizing genes on the association of meat intake and HCA exposure with colorectal polyp risk.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 981802734 for PMID:18268115 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2000 Jun;9(3):151-64 [10954254.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2789-95 [16393237.001]
  • [Cites] Pharmacogenetics. 2001 Apr;11(3):207-15 [11337936.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):601-7 [11477566.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1307-13 [11535705.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1681-4 [11577009.001]
  • [Cites] Anal Biochem. 2002 Feb 15;301(2):328-32 [11814304.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):241-56 [11857415.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Eur J Nutr. 2002 Feb;41(1):35-43 [11990006.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1126-33 [12165637.001]
  • [Cites] Pharmacogenetics. 2002 Aug;12(6):473-8 [12172216.001]
  • [Cites] Chem Biol Interact. 2002 Sep 20;141(1-2):161-87 [12213390.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:205-14 [12351160.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):99-107 [16434594.001]
  • [Cites] Pharmacogenet Genomics. 2006 Apr;16(4):237-43 [16538170.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1649-58 [16550165.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1208-11 [16570281.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):774-9 [16800822.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1703-7 [16985033.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):328-41 [16926176.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):136-42 [17354224.001]
  • [Cites] Pharmacogenomics J. 2008 Oct;8(5):339-48 [17909564.001]
  • [Cites] Am J Epidemiol. 2000 May 1;151(9):846-61 [10791558.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):529-32 [10815700.001]
  • [Cites] Br J Clin Pharmacol. 2002 Nov;54(5):504-10 [12445029.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):68-76 [12534642.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1130-6 [14652271.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1295-304 [14984001.001]
  • [Cites] Int J Epidemiol. 2004 Feb;33(1):17-21 [15075140.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):225-36 [15090717.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):159-64 [15167213.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1839-45 [1934265.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3043-9 [7606725.001]
  • [Cites] Lancet. 1996 May 18;347(9012):1372-4 [8637343.001]
  • [Cites] Cancer Causes Control. 1996 Jul;7(4):479-86 [8813437.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2125-9 [8895478.001]
  • [Cites] Gut. 1998 Mar;42(3):402-9 [9577349.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3307-11 [9699660.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):15-24 [9950235.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):69-75 [9950242.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2242-55 [15555008.001]
  • [Cites] Nutr Rev. 2004 Nov;62(11):427-38 [15622715.001]
  • [Cites] Carcinogenesis. 2005 Mar;26(3):637-42 [15579480.001]
  • [Cites] Mol Nutr Food Res. 2005 Jul;49(7):648-55 [15986387.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8034-41 [16140978.001]
  • [Cites] Cancer Lett. 2005 Nov 8;229(1):25-31 [16157215.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1041-54 [16184469.001]
  • [Cites] Mutat Res. 2005 Nov 10;587(1-2):59-66 [16188490.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):311-7 [16153594.001]
  • [Cites] Drug Metab Dispos. 2000 Dec;28(12):1425-32 [11095579.001]
  • (PMID = 18268115.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA950103; United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / CA095103-010005; United States / NCI NIH HHS / CA / R01 CA097386-01; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / R01 CA034627; United States / NCI NIH HHS / CA / CA097386-01; United States / NCI NIH HHS / CA / R01 CA34627; United States / NCI NIH HHS / CA / R01 CA034627-15; United States / NCI NIH HHS / CA / P50 CA095103-010005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.3.1.- / Acetyltransferases
  • [Other-IDs] NLM/ NIHMS72769; NLM/ PMC2572782
  •  go-up   go-down


11. Fukui M, Fujino T, Tsutsui K, Maruyama T, Yoshimura H, Shinohara T, Fukui M, Nada O: The tumor-preventing effect of a mixture of several lactic acid bacteria on 1,2-dimethylhydrazine-induced colon carcinogenesis in mice. Oncol Rep; 2001 Sep-Oct;8(5):1073-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The animals were sacrificed either 15 weeks or 24-26 weeks after the first carcinogen injection.
  • Histologically, microadenomas were induced predominantly in the anal half of the total colon, and large lymphoid aggregates were often associated with dysplastic crypts in the distal colon.
  • From the present results, it is suggested that the intake of the dietary supplement inhibits the early development of colon adenomas, and the inhibition of microadenomas results in a reduction of subsequent polyp and tumor yield in the mouse colon.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Colon / microbiology. Dietary Supplements. In Situ Nick-End Labeling. Lactic Acid / metabolism. Male. Mice. Mice, Inbred ICR

  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496319.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 33X04XA5AT / Lactic Acid; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


12. Bayyurt N, Abasiyanik MF, Sander E, Salih BA: Canonical correlation analysis of factors involved in the occurrence of peptic ulcers. Dig Dis Sci; 2007 Jan;52(1):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The variables measured are endoscopic findings (DU, GU, antral gastritis, erosive gastritis, pangastritis, pyloric deformity, bulbar deformity, bleeding, atrophy, Barret esophagus and gastric polyp) and risk factors (age, gender, Helicobacter pylori infection, smoking, alcohol, and nonsteroidal anti-inflammatory drugs [NSAIDs] and aspirin intake).
  • [MeSH-minor] Adult. Alcohol Drinking / epidemiology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Barrett Esophagus / epidemiology. Endoscopy, Gastrointestinal. Female. Gastritis / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori. Humans. Male. Middle Aged. Multivariate Analysis. Risk Factors. Smoking / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3811-6 [15991274.001]
  • [Cites] Am J Epidemiol. 1998 Mar 15;147(6):529-36 [9521179.001]
  • [Cites] Epidemiology. 1997 Jul;8(4):420-4 [9209857.001]
  • [Cites] J Epidemiol Community Health. 1994 Apr;48(2):156-60 [8189170.001]
  • [Cites] Helicobacter. 2004 Jun;9(3):249-54 [15165261.001]
  • [Cites] BMJ. 1997 Dec 6;315(7121):1489-92 [9420488.001]
  • [Cites] Am J Epidemiol. 1992 Mar 1;135(5):521-30 [1570818.001]
  • [Cites] J Clin Gastroenterol. 1997 Jan;24(1):2-17 [9013343.001]
  • [Cites] Can J Gastroenterol. 2002 Aug;16(8):527-32 [12226680.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Sep;11(9):825-31 [8889960.001]
  • [Cites] Addict Behav. 2001 Jan-Feb;26(1):137-42 [11196288.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Accid Anal Prev. 2003 Nov;35(6):903-12 [12971925.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):497-506 [11876703.001]
  • [Cites] J Gastroenterol. 1999 Aug;34(4):455-60 [10452677.001]
  • [Cites] Gut. 2003 Feb;52(2):186-93 [12524398.001]
  • [Cites] Digestion. 2005;71(4):231-7 [16024928.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):515-9 [11194733.001]
  • (PMID = 17180541.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


13. Sweetser S, Alexander GL, Boardman LA: A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol; 2010 Aug;7(8):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps.
  • In the past, he had experienced markedly increased levels of triglycerides and was being treated for this condition with a lipid-lowering agent.
  • DIAGNOSIS: Cronkhite-Canada syndrome.
  • Removal of all visible polyps from the anal verge to 25 cm endoscopically by snare polypectomy or with hot biopsy forceps, followed by subtotal colectomy with end-to-side ileorectostomy.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Colon / pathology. Intestinal Polyposis / drug therapy. Intestinal Polyposis / pathology. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Steroids.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cronkhite-canada syndrome .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628344.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Histamine H2 Antagonists; 0 / Vitamins; VB0R961HZT / Prednisone
  •  go-up   go-down


14. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1035-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Familialadenomatous polyposis (FAP) is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual colorectal cancer.
  • Regression of adenomas in this syndrome occurs with the administration of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, but these compounds can have considerable side effects.
  • METHODS: Five FAP patients with prior colectomy (4 with retained rectum and 1 with an ileal anal pouch) received curcumin 480 mg and quercetin 20 mg orally 3 times a day.
  • The number and size of polyps were assessed at baseline and after therapy.
  • The Wilcoxon signed-rank test was used to determine differences in the number and size of polyps.
  • Treatment side effects and medication compliance also were evaluated.
  • RESULTS: All 5 patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment with curcumin and quercetin.
  • The mean percent decrease in the number and size of polyps from baseline was 60.4% (P < .05) and 50.9% (P < .05), respectively.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Antineoplastic Agents / therapeutic use. Antioxidants / therapeutic use. Curcumin / therapeutic use. Quercetin / therapeutic use
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Sigmoidoscopy


15. Gholam P, Autschbach F, Hartschuh W: Schistosomiasis in an HIV-positive patient presenting as an anal fissure and giant anal polyp. Arch Dermatol; 2008 Jul;144(7):950-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schistosomiasis in an HIV-positive patient presenting as an anal fissure and giant anal polyp.
  • [MeSH-major] Anus Diseases / diagnosis. Fissure in Ano / diagnosis. HIV Infections. Schistosomiasis / diagnosis
  • [MeSH-minor] Adult. Animals. Anthelmintics / administration & dosage. Anthelmintics / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Polyps / diagnosis. Polyps / drug therapy. Polyps / pathology. Polyps / surgery. Praziquantel / administration & dosage. Praziquantel / therapeutic use. Schistosoma mansoni / isolation & purification. Viral Load






Advertisement